Device specific vigilance guidance: Coronary Stents and associated delivery systems

AI Summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued guidance to supplement the Medical Devices Regulations (Statutory Instrument 2024 No. 1368), focusing on post-market surveillance for coronary stents. While this document is not an inspection report and lacks specific inspection dates, it serves as a critical regulatory framework for manufacturers to report device performance issues and clinical complications. The guidance outlines three distinct reporting categories based on incident severity. First, serious individual incidents—such as heart attacks, arterial perforations, cardiogenic shock, and severe allergic reactions—must be reported immediately. This also includes mechanical failures like stent fractures, delivery system breakages, or balloon deflation issues. Second, manufacturers may use Periodic Summary Reports for agreed-upon events, including stent narrowing, strokes within 12 months of a procedure, or stent deformation. Third, trend reporting is required if there is a significant increase in the frequency or severity of complications like infections, minor bleeding, or navigation difficulties. Required actions for manufacturers include implementing robust monitoring systems, categorizing incidents using International Medical Device Regulators Forum (IMDRF) codes, and ensuring timely submissions even if incidents overlap multiple categories. This ensures a continuous risk analysis and aligns manufacturer practices with current European Society of Cardiology clinical guidelines.